204 related articles for article (PubMed ID: 20234340)
1. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
Liu C; Russell SJ; Peng KW
Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
3. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
Dingli D; Peng KW; Harvey ME; Greipp PR; O'Connor MK; Cattaneo R; Morris JC; Russell SJ
Blood; 2004 Mar; 103(5):1641-6. PubMed ID: 14604966
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
5. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.
Ong HT; Federspiel MJ; Guo CM; Ooi LL; Russell SJ; Peng KW; Hui KM
J Hepatol; 2013 Nov; 59(5):999-1006. PubMed ID: 23867315
[TBL] [Abstract][Full Text] [Related]
6. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
[TBL] [Abstract][Full Text] [Related]
8. Enhancing cytokine-induced killer cell therapy of multiple myeloma.
Liu C; Suksanpaisan L; Chen YW; Russell SJ; Peng KW
Exp Hematol; 2013 Jun; 41(6):508-17. PubMed ID: 23403007
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW; Dogan A; Vrana J; Liu C; Ong HT; Kumar S; Dispenzieri A; Dietz AB; Russell SJ
Am J Hematol; 2009 Jul; 84(7):401-7. PubMed ID: 19507209
[TBL] [Abstract][Full Text] [Related]
11. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
[TBL] [Abstract][Full Text] [Related]
13. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
15. Interaction of measles virus vectors with Auger electron emitting radioisotopes.
Dingli D; Peng KW; Harvey ME; Vongpunsawad S; Bergert ER; Kyle RA; Cattaneo R; Morris JC; Russell SJ
Biochem Biophys Res Commun; 2005 Nov; 337(1):22-9. PubMed ID: 16171777
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
[TBL] [Abstract][Full Text] [Related]
18. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.
Hutzen B; Pierson CR; Russell SJ; Galanis E; Raffel C; Studebaker AW
BMC Cancer; 2012 Nov; 12():508. PubMed ID: 23134812
[TBL] [Abstract][Full Text] [Related]
19. Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice.
Lal S; Peng KW; Steele MB; Jenks N; Ma H; Kohanbash G; Phillips JJ; Raffel C
Hum Gene Ther Clin Dev; 2016 Dec; 27(4):145-151. PubMed ID: 27604429
[TBL] [Abstract][Full Text] [Related]
20. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.
Hallak LK; Merchan JR; Storgard CM; Loftus JC; Russell SJ
Cancer Res; 2005 Jun; 65(12):5292-300. PubMed ID: 15958576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
